{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:46:07Z","timestamp":1777416367565,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"am","delay-in-days":440,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bulcan.2021.08.001","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:33:41Z","timestamp":1639568021000},"page":"S40-S54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S","title":["CAR T-cells in acute lymphoblastic leukemia: Current results"],"prefix":"10.1016","volume":"108","author":[{"given":"Marie Emilie","family":"Dourthe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bulcan.2021.08.001_bib0330","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2021.08.001_bib0335","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.08.001_bib0340","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed\/Refractory (r\/r) Acute Lymphoblastic Leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bulcan.2021.08.001_bib0345","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2021.08.001_bib0350","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"15","key":"10.1016\/j.bulcan.2021.08.001_bib0355","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2021.08.001_bib0360","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"issue":"9967","key":"10.1016\/j.bulcan.2021.08.001_bib0365","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0370","article-title":"Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2021.08.001_bib0375","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"224","key":"10.1016\/j.bulcan.2021.08.001_bib0380","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.bulcan.2021.08.001_bib0385","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2021.08.001_bib0390","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2019.37.15_suppl.7006","article-title":"End of phase I results of ZUMA-3, a phase 1\/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL)","volume":"37","author":"Shah","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2021.08.001_bib0395","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"Jacoby","year":"2018","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.bulcan.2021.08.001_bib0400","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.08.001_bib0405","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-134472","article-title":"Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)","volume":"136","author":"Schultz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0410","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.bulcan.2021.08.001_bib0415","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0420","series-title":"ASH","article-title":"Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme","author":"Ghorashian","year":"2020"},{"issue":"Supplement_1","key":"10.1016\/j.bulcan.2021.08.001_bib0425","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1182\/blood-2019-131123","article-title":"Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience","volume":"134","author":"Dourthe","year":"2019","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2021.08.001_bib0430","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2019.37.15_suppl.2520","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL","volume":"37","author":"Perica","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2021.08.001_bib0435","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.bulcan.2021.08.001_bib0440","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0445","first-page":"130","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"issue":"Supplement_1","key":"10.1016\/j.bulcan.2021.08.001_bib0450","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2019-130060","article-title":"Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy","volume":"134","author":"Barz Leahy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0455","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","author":"Sheth","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2021.08.001_bib0460","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"499","key":"10.1016\/j.bulcan.2021.08.001_bib0465","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0470","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive Mitigation of CD19 CAR T Cell Cytokine Release Syndrome Without Attenuation of Anti-Leukemic Efficacy","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.bulcan.2021.08.001_bib0475","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1182\/blood-2019-127346","article-title":"Tisagenlecleucel Manufacturing Feasibility in Patients Less Than 3 Years of Age with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"134","author":"Eldjerou","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.08.001_bib0480","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139260","article-title":"Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival","volume":"136","author":"Taraseviciute","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2021.08.001_bib0485","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"Supplement_2","key":"10.1016\/j.bulcan.2021.08.001_bib0490","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-132435","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0495","series-title":"ASH","article-title":"A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed\/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study","author":"Brivio","year":"2020"},{"issue":"1","key":"10.1016\/j.bulcan.2021.08.001_bib0500","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/hematology.2020000172","article-title":"CAR T cells vs allogeneic HSCT for poor-risk ALL","volume":"2020","author":"Diorio","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0505","article-title":"Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study","author":"Peters","year":"2020","journal-title":"J Clin Oncol [Internet]"},{"issue":"22","key":"10.1016\/j.bulcan.2021.08.001_bib0510","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine\/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bulcan.2021.08.001_bib0515","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.08.001_bib0520","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2018-99-117445","article-title":"Phase 1 Study of CD19\/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)","volume":"132","author":"Schultz","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.bulcan.2021.08.001_bib0525","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2019-123424","article-title":"Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia (r\/r B-ALL): Amelia Study","volume":"134","author":"Amrolia","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.08.001_bib0530","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.08.001_bib0535","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2018-99-113714","article-title":"CAR22\/19 Cocktail Therapy for Patients with Refractory\/Relapsed B-Cell Malignancies","volume":"132","author":"Huang","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2021.08.001_bib0540","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.08.001_bib0545","first-page":"1319","article-title":"Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"130","author":"Maude","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0550","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2021.08.001_bib0555","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.bulcan.2021.08.001_bib0560","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"374","key":"10.1016\/j.bulcan.2021.08.001_bib0565","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"issue":"10266","key":"10.1016\/j.bulcan.2021.08.001_bib0570","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.bulcan.2021.08.001_bib0575","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2021.08.001_bib0580","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2021.08.001_bib0585","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.2017.35.15_suppl.103","article-title":"The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL)","volume":"35","author":"Maude","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.08.001_bib0590","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/hematology.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"2020","author":"Basar","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0595","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","author":"Liu","year":"2020","journal-title":"N Engl J Med [Internet]"},{"issue":"1","key":"10.1016\/j.bulcan.2021.08.001_bib0600","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/hematology.2020000134","article-title":"CAR T cells for other pediatric non-B-cell hematologic malignancies","volume":"2020","author":"Lamble","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.bulcan.2021.08.001_bib0605","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u2018off-the-shelf\u2019 fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bulcan.2021.08.001_bib0610","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2021.08.001_bib0615","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.bulcan.2021.08.001_bib0620","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bulcan.2021.08.001_bib0625","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/s41375-019-0455-3","article-title":"Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies","volume":"33","author":"Huang","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0630","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bulcan.2021.08.001_bib0635","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99442","article-title":"TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy","volume":"3","author":"Rasaiyaah","year":"2018","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.bulcan.2021.08.001_bib0640","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2021.08.001_bib0645","article-title":"Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management","author":"Li","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"Supplement_1","key":"10.1016\/j.bulcan.2021.08.001_bib0650","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed\/Refractory T-Cell Malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:35:19Z","timestamp":1757792119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121002836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0007455121002836"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.08.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cells in acute lymphoblastic leukemia: Current results","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}